BioXcel Therapeutics price target lowered to $1 from $4 at BofA
BofA analyst Alec Stranahan lowered the firm’s price target on BioXcel Therapeutics (BTAI) to $1 from $4 and keeps an Underperform rating on ...
Zacks Investment Research on MSN3d
BioXcel Therapeutics, Inc. (BTAI) Reports Q4 Loss, Tops Revenue Estimates
BioXcel Therapeutics, Inc. (BTAI) came out with a quarterly loss of $3.57 per share versus the Zacks Consensus Estimate of a loss of $4.36. This compares to loss of $12.16 per share a year ago. These ...
Wall Street Journal8d
Xcell Therapeutics Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
BioXcel Therapeutics reports Q4 EPS ($3.57), consensus ($5.14)
Reports Q4 revenue $366k, consensus $718.26k. “We believe that our SERENITY program presents an exciting opportunity to address a substantial ...